Displaying 641 - 660 of 1557
FTC Staff Provides Comments to FDA on Naming Proposal for Biologic Products
Concurring Statement of Commissioner Julie Brill on the Joint Statement of the Federal Trade Commission and the Antitrust Division of the U.S. Department of Justice to the Virginia Certificate of Public Need Work Group
Agencies Submit Joint Statement Regarding Virginia Certificate-of-Need Laws for Health Care Facilities
Pfizer Inc./Hospira, Inc., In the Matter of
Pfizer Inc. agreed to sell the rights and assets related to four pharmaceutical products in order to settle FTC charges that its proposed $16 billion acquisition of Hospira, Inc. would likely be anticompetitive. Pfizer is one of the world’s largest drug companies and principally competes with Hospira in markets for certain sterile injectable pharmaceutical products. The order requires Pfizer to supply Alvogen with the clindamycin phosphate injection product for three years while Pfizer transfers the manufacturing technology to Alvogen or its designee. Pfizer also is required to provide transitional services to Alvogen to assist with establishing manufacturing capabilities and securing FDA approvals to market all of the divested products.
Two Pennsylvania Orthopedic Practices Settle FTC Charges That Merger Harmed Competition and Inflated Prices
In Comments Submitted to Virginia and Tennessee Health Departments FTC Staff Offers Assistance in Evaluating Proposed Hospital Cooperation Agreements
FTC Files Amicus Brief Explaining that Pharmaceutical “Product Hopping” Can Violate the Antitrust Laws
Mylan Pharmaceuticals, Inc. v. Warner Chilcott plc, et al.
FTC Returns Money to Consumers Tricked into Buying Phony Health Insurance
FTC Posts Agenda for September 21 Workshop to Examine Advertising for Over-the-Counter Homeopathic Products
Zimmer Holdings, Inc. / Biomet, Inc., In the Matter of
Medical device company Zimmer Holdings, Inc. agreed to divest U.S. rights and assets related to unicondylar knee implants, total elbow implants, and bone cement in order to settle FTC charges that its proposed $13.35 billion acquisition of Biomet Inc. is anticompetitive. According to the complaint, Zimmer and Biomet are two of the only three substantial competitors in the U.S. markets for unicondylar knee implants and total elbow implants, and two of only four significant competitors in the U.S. market for bone cement. The order requires Zimmer to divest to Smith & Nephew the U.S. intellectual property, manufacturing technology, and existing inventory relating to its unicondylar knee implant, and to provide transitional services to help them establish manufacturing capabilities and secure necessary FDA approvals. The order also requires Biomet to divest to DJO the U.S. intellectual property, manufacturing technology, and existing inventory relating to its total elbow implant and bone cement products, and it facilitates DJO’s hiring of the Biomet sales representatives and other staff who work with these products.
Statement of Chairwoman Edith Ramirez In the Matter of LabMD, Inc.
FTC Action: Scammers Banned from Selling Healthcare Products
FTC Staff Comment, and Concurring Comment of Commissioner Wright, Regarding North Carolina House Bill 200, Which Would Exempt Diagnostic Centers, Ambulatory Surgical Facilities and Psychiatric Hospitals From Certificate of Need Regulation
FTC Staff Supports North Carolina Legislative Proposal to Limit Certificate of Need Rules for Health Care Facilities
Plymouth Direct, Inc. (BeActive Brace)
FTC Staff Urges Minnesota Legislature to Weigh Benefits and Risks of Disclosing Terms of State Health Care Services Contracts
Displaying 641 - 660 of 1557